Stacking
Tirzepatide is most commonly used as a standalone therapy, but is occasionally combined with other agents in clinical or research contexts.
Metformin
The most common combination in type 2 diabetes management. Metformin provides complementary glycemic benefits through insulin sensitization and hepatic glucose output reduction, operating through entirely different mechanisms. The combination is generally well-tolerated and may reduce total required tirzepatide dose.
SGLT2 Inhibitors
Agents such as empagliflozin or dapagliflozin add approximately 2–3 kg of additional weight loss through glucosuria while providing established cardiovascular and renal protective effects independent of glycemic control. This combination is increasingly used in patients with type 2 diabetes and high cardiovascular risk.
Testosterone Replacement Therapy
In hypogonadal men, concurrent testosterone replacement may help preserve lean mass during the significant weight loss produced by tirzepatide, given that 25–40% of weight lost may otherwise be lean tissue.
Not Recommended:
- Other GLP-1 receptor agonists (overlapping mechanisms, no additive benefit, increased side effect burden), including emerging options like retatrutide
- Concurrent insulin without careful dose reduction and hypoglycemia monitoring (significant hypoglycemia risk)